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Welcome to the newly revamped journal of Applied & Translational
Genomics (ATG). ATG is a new open access biomedical journal provid-
ing a global forum for ‘omics’ research, converging disruptive technolo-
gies, clinical genomics, and related issues in education, bioethics, public
health, citizen science and policy. The journal's mission is to enhance
knowledge sharing and discussion of applied and translational geno-
mics worldwide. With the assistance of my committed and esteemed
Editorial Boardmembers, ATGwill reach deep into otherwise less recog-
nized and resourced areas of the world to give voice to quality research,
analyses and commentary. Thus, the new ATG is a bold, but nonetheless
important, initiative.
This inaugural issue covers key cutting edge interdisciplinary areas
at the forefront of translational and applied genomics and thus differen-
tiates the journal. In content, we cover original research, an analysis of
the meaning of translational genomics, a report on convergent innova-
tive informatics applications and another on proposed initiatives to im-
prove the integration of a molecular approach to targeted cancer
medicine, database and data infrastructure reviews, a commentary, a
FDA regulation and consumer rights to access their genome and a
correspondence.
Of paramount importance is Kussman and Kaput's ‘Translational Ge-
nomics’ because it lays out the journal's deﬁnition of the ‘translational
and applied genomics’, clarifying what we mean, and what we do not
mean. Historically, ‘applied’ research was considered a development
(R & D) and as such distinct from basic, pre-clinical, research. The
view of the authors, and the journal for thatmatter, is that a newmean-
ing is more apt. Translational and applied genomics now incorporates
the relatively nascent ﬁelds of systems thinking, real time monitoring,
big data, and predictive analytics, evidence-based solutions and patient
participation at all points in the lifecycle. In this way, translational re-
search focuses on ‘relevance’ to human health. The authors articulate
how andwhy translational human genomics research extends function-
al science to include the use of ‘omics’ to capture the dynamism of bio-
logical processes and environmental exposures. With this new focus,
translational omics will increasingly make use of longitudinal data gen-
erated by the ever more quantiﬁed individual, combining ‘the best sci-
ence with applications in real time’, thus debunking the idea that
‘translational’ and ‘basic’ research are distinctly different activities. In
sum, Kussman and Kaput convincingly show how this new deﬁnition
of translational omics research can generate high impact solutions ap-
plied in real time to assess, mitigate, improve or delay disease symp-
toms, and thus maintain health.http://dx.doi.org/10.1016/j.atg.2014.08.001
2212-0661/© 2014 Published by Elsevier B.V.Artiﬁcial super intelligence is rapidly expanding its grip on basic
tasks of everyday life. The increased use of sequencing and real time
monitoring data output far outpaces our ability to harness and effective-
ly use it. Engineered intelligent software systems are emerging to meet
this need. Naik and Bhide provide a brief update and reﬂection of how
these intelligence systems automate routine cognitive tasks used in
knowledge processing and thus solve signiﬁcant gap in utilizing and un-
derstanding generated data in a uniﬁed platform.
The authors explain how second generation automated knowledge
management is accomplishing complex and varied workﬂow tasks in
genomic research. High throughput screening (HTS), next generation
sequencing, genome, exome and ome sequencing are clearly generating
massive amounts of biological data. HTS quickly conducts a large num-
ber of pharmacological, chemical or genetic tests. NGS sequences RNA
transcriptomes to produce high deﬁnition views of transcript sequence,
SNP haplotypes, rare variants, splicing, exon boundaries and RNA
editing. Automated technologies can swiftly sift through existing
knowledge to identify, tag genes, antibodies or active compounds in
real time. Accomplishing such complex and varied tasks requires com-
puter intelligence that can learn, namely, continually build on the new
knowledge it generates, not just do. Naik and Bhide artfully describe
two different Optra solutions for genomic knowledge management;
Optra Bio-NLP that generates genomic knowledge from the biomedical
literature and then auto-populates it into legacy databases; and a plat-
form that detects, demarcates and annotates regions of interest in med-
ical imaging. Challenges to ensuring that these systems are full-proof
and concomitant ethical issues are raised.
It is widely known that tumor heterogeneity is common within and
between tumors, and affects both cancer pathways and phenotypic var-
iation. Tumor sample heterogeneity is a limitation in somatic mutation
detection and thus challenge to personalized cancer medicine.
Watanabe et al. report their success in overcoming detection limitations
due to heterogeneity. Using simultaneous genome and single cell iden-
tiﬁcation using semiconductor based next generation sequencing they
were able to discriminate A549 cancer cells from a bulk population of
A549 cells, thus eliminating the problem of somatic variant detection
in the presence of tumor heterogeneity. The success of their approach
is an important step forward in both overcoming the limitations of cur-
rent somatic mutation detection methods and personalizing oncology.
Knowledge derived along the path from variant detection to variant
interpretation to clinical signiﬁcance is frequently discussed but a de-
tailed analysis of the basis for limitations in that ‘knowledge’ is infre-
quent at best. Quintans et al. contribute a thorough elucidation of
these limitations and difﬁculties. Imprecise and incorrect use of terms
results in mischaracterizations and falsely attributed causation. Further,
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interpretation is based only on annotations of variant functional conse-
quences using databases stored in, or linked to, the same repository.
The authors further show how stepwise and linear interpretation pro-
cesses are likely to overrate some pieces of evidence while underrating
others. They call for accurate and consistent use of terms and algorithms
that permit a multidimensional parallel analysis of diverse evidence for
speciﬁc genes, cellular pathways or disorders. Their conclusion rein-
forces the appropriateness of Kussman and Kaput's deﬁnition of transla-
tional genomics.
Bennetts et al. report the new collaborative effort on the part of the
Human Variome Project (http://www.humanvariomeproject.org/), the
Royal College of Pathologists of Australasia and the Human Genetics So-
ciety of Australasia to develop quality standards for gene variant data-
bases. The authors brieﬂy discuss some of the many initiatives, white
papers, best practices, policy statements and guidelines that address as-
pects of responsible integration of emerging genomic technologies into
mainstream clinical diagnostics. The collaboration is designed to estab-
lish standards for accuracy, quality and ongoing data maintenance to
ensure that a data repository meets the needs of the clinical diagnostic
environment. When completed, the project will have demonstrated
the feasibility of creating a networked quality data standard that is
aligned with both existing laboratory standards and accreditation re-
quirements, as well as guidelines and new initiatives while settingmin-
imum requirements for clinical purposes within the boundaries of
existing national and global legislation. This achievement will mark an
important step in advancing the clinical application of gene variant
knowledge.
The path from availablemolecular based technologies and treatments
to individual and societal beneﬁts of targeted cancer medicine is lined
with challenges in aligning proven clinical research with care delivery
systems. Leading research and clinical oncology experts recently con-
vened to identify top unmet needs and recommend solution strategies.
Flynn and Van Dam report on eight strategic initiatives ranging in scope
from the need for a sustainable patient/tumor genotype/phenotype reg-
istry for research and clinical use to better dissemination of new clinical
knowledge and tools to community care providers who lack the re-
sources of large academic medical centers.Without people there is no translational and applied genomics. For
this reason, some bioethicists argue that justice commands reciprocity
between researchers and donors, in part because in practice reciprocal
rights and obligations are not the norm. Regulation of access to genomic
information intends to fairly balance society's right to protect the public
against the effects of ineffective and harmful genomic technologies, and
a person's right to learn what's in their genes. However, the balance of
burdens and beneﬁts set is not without controversy on various levels.
Angrist analyzes the 23 &Me/FDA debacle as a case in point, raising im-
portant questions about when and how regulation can inappropriately
stand in the way of people, healthy or sick, and their genomes.
Note that we publish a letter to the Editor regarding the use of
Hardy–Weinberg equilibrium in the previous ATG article “Association
of polymorphism in cytochrome P450 2C9 with susceptibility to head
and neck cancer and treatment outcome” (Yadav et al., 2014). We en-
courage correspondence and lively, even provocative, discussion.
Finally, in the Apology, Platowrites, “the greatest good for aman (is)
to discuss virtue (excellence) every day and those other things about
which you hear me conversing and testing myself and others, for the
unexamined life is not worth living for men.” (38a) A life focused on
the question of its greatest good is a life lived to its fullest, that is, an ex-
cellent, or virtuous, life. Plato's concept of wisdom emphasizes the need
to put understanding into practice; to make a difference not only in
one's life but also in the lives of others. The journal's view is that trans-
lational and applied genomics instantiates knowledge into practice and
in doing so makes a difference in the lives of all, wherever situated
around the globe.
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